May 4, 2018 / 1:54 AM / 7 months ago

BRIEF-U.S. FDA Approves Portola Pharmaceuticals’ Andexxa

May 3 (Reuters) - Portola Pharmaceuticals Inc:

* U.S. FDA APPROVES PORTOLA PHARMACEUTICALS’ ANDEXXA®, FIRST AND ONLY ANTIDOTE FOR THE REVERSAL OF FACTOR XA INHIBITORS

* SAYS STUDY IS SCHEDULED TO BE INITIATED IN 2019 AND BE REPORTED IN 2023

* PORTOLA PHARMACEUTICALS - BROADER COMMERCIAL LAUNCH IS ANTICIPATED IN EARLY 2019 UPON FDA APPROVAL OF ITS GENERATION 2 MANUFACTURING PROCESS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below